Deb Kientop
![Deb Kientop Deb Kientop](https://cytokine-based-drugdevelopment.com/wp-content/uploads/sites/349/2024/04/ec8cff0a-0608-11ef-bad1-0242ac110003-150x150.jpg)
Company: DEKA Biosciences
Job title: Vice President, Clinical Operations
Seminars:
Updating the Clinical Progress of DK210 (EGFR), Fusing IL-10 With wtIL-2 to Prevent Toxicity & Enhance Potency 11:00 am
Treating patients with cold tumors has already elicited potent peripheral immune activation leading to confirmed stable disease of stage 4 PDAC, and unconfirmed stable disease of patients with stage 4 CRC Indicating DK210 (EGFR) has successfully blunted IL-2 inflammatory toxicity while retaining potent immunological activation and dramatically improved its therapeutic index Outlining how responses stimulated…Read more
day: Conference Day One